Degarelix: structure, approved use, key trials and status

Degarelix is a synthetic GnRH receptor antagonist first approved by FDA in 2008 as Firmagon. This guide covers its structure, label, key human trials and status as of November 17, 2026.

Complete guide6 min read

Key takeaway

Degarelix is a GnRH receptor antagonist, a ten-amino-acid peptide with seven unnatural amino acids. FDA approved Firmagon on December 24, 2008. In its pivotal trial of 610 men, testosterone stayed at castration levels for a year in 97.2% on degarelix and 96.4% on leuprolide. By day 3, 96% on degarelix had reached that level, versus none on leuprolide. The label carries no boxed warning.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“FDA first approved degarelix in 2008 as Firmagon.” (this article)
ClassReproductive hormones
Body systemsReproductive system
Studies cited3 in this article · 3 across 1 article on Degarelix
Related productsResearch peptide catalog

Degarelix is a synthetic peptide that blocks the receptor for gonadotropin-releasing hormone (GnRH) in the pituitary gland. FDA approved it as Firmagon in 2008 for advanced prostate cancer. Unlike GnRH agonists, it blocks the receptor rather than first stimulating it. This guide covers its structure, label, trials and status, using sources checked on November 17, 2026.

Quick answer: Degarelix is a prescription GnRH antagonist sold as Firmagon. Its label approves it for “treatment of patients with advanced prostate cancer.” It blocks pituitary GnRH receptors, so less luteinizing hormone is released and testosterone falls. Local site reactions, hot flashes and liver enzyme increases are its most common label side effects.

Vitrapep does not sell degarelix; this page is a reference summary of published research and regulatory information. It is not medical advice.

What is degarelix?

Degarelix is a short synthetic peptide. The FDA label describes it as “a synthetic linear decapeptide amide containing seven unnatural amino acids, five of which are D-amino acids” (Firmagon label, 2020). Decapeptide means a chain of ten amino acids. Unnatural amino acids are ones not among the standard building blocks of proteins.

PubChem lists the formula C82H103ClN18O16 and a molecular weight of 1632.3 g/mol (PubChem CID 16136245). The label gives the same weight.

Ferring Pharmaceuticals makes Firmagon. FDA’s Drugs@FDA report for that month lists its original approval on December 24, 2008, as a Type 1 new molecular entity (Drugs@FDA, December 2008). FDA first approved degarelix in 2008 as Firmagon. For background on this hormone family, see our overview of peptide hormones.

Table 1

Degarelix: key facts

Fact Detail
Structure Linear peptide of ten amino acids with a C-terminal amide; seven unnatural amino acids, five of them D-amino acids
Class GnRH receptor antagonist
Molecular formula C82H103ClN18O16 (PubChem)
Molecular weight 1632.3 g/mol (PubChem)
First FDA approval December 24, 2008 (Firmagon)
Brand names Firmagon

How does degarelix work?

The label states: “Degarelix is a GnRH receptor antagonist. It binds reversibly to the pituitary GnRH receptors.” This reduces “the release of gonadotropins and consequently testosterone” (Firmagon label, 2020).

In plain terms, the hypothalamus sends GnRH to the pituitary. The pituitary answers with luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH drives testosterone production. Degarelix sits in the GnRH receptor and blocks the signal. GnRH agonists such as goserelin and leuprolide work differently. They first stimulate the receptor, which causes a temporary hormone rise, before suppressing it.

Early animal work showed the same profile. In rats and monkeys, degarelix gave long-lasting suppression of LH. The pattern fit competitive blocking of the receptor (Broqua et al., 2002). Those are animal data.

What is degarelix approved for?

Section 1 of the label has one indication: “FIRMAGON® is indicated for treatment of patients with advanced prostate cancer” (Firmagon label, 2020). The label lists no other indication.

What did the key trials of degarelix show?

CS21 (pivotal trial). This open-label phase 3 trial randomized 620 men with prostate cancer who needed androgen deprivation (NCT00295750). It compared two degarelix regimens with leuprolide for one year. The primary endpoint was testosterone at or below 0.5 ng/mL from day 28 to day 364.

In the 610 men analyzed, the rates were 97.2% and 98.3% for the degarelix groups and 96.4% for leuprolide. The authors concluded that degarelix “was not inferior to leuprolide” at keeping testosterone low over one year. At day 3, about 96% on degarelix had testosterone at or below that level, versus none on leuprolide. Median PSA was lower with degarelix at days 14 and 28 (P<0.001) (Klotz et al., 2008). These are human data.

PRONOUNCE (heart safety). This trial compared degarelix and leuprolide in men with prostate cancer and known atherosclerotic heart or vessel disease (NCT02663908). It randomized 545 men and stopped early because of slow enrollment and fewer events than expected. Major cardiovascular events occurred in 5.5% on degarelix and 4.1% on leuprolide. The hazard ratio was 1.28 (95% CI 0.59 to 2.79; P=0.53). The authors said the relative heart safety of the two drug classes remains unresolved (Lopes et al., 2021).

What side effects does the degarelix label list?

The label has no boxed warning. It lists the most common adverse reactions, at 10% or more. They are “injection site reactions (e.g., pain, erythema, swelling or induration), hot flashes, and increases in serum levels of transaminases and gamma-glutamyltransferase (GGT)” (Firmagon label, 2020).

In the pivotal trial table, rates for degarelix versus leuprolide were:

  • local site reactions: 35% versus less than 1%;
  • hot flash: 26% versus 21%;
  • increases in transaminases and GGT: 10% versus 5%;
  • weight increase: 9% versus 12%; and
  • urinary tract infection: 5% versus 9%.

The label’s warnings cover hypersensitivity reactions, including anaphylaxis, urticaria and angioedema reported after marketing. They also cover QT interval prolongation, effects on laboratory tests and embryo-fetal toxicity. Changes in bone density are listed from postmarketing experience.

What is degarelix’s regulatory status, and is it used in research?

Firmagon is a prescription drug. The current DailyMed label is dated February 2020.

WADA’s 2026 Prohibited List does not name degarelix (WADA, 2026). Its section S2.2.1 covers “Testosterone-stimulating peptides in males.” The examples are chorionic gonadotrophin, LH, kisspeptin, and GnRH “and its agonist analogues.” Degarelix is an antagonist. Section S2 also covers substances with “similar chemical structure or similar biological effect(s).” Athletes should check with their anti-doping organization. Our guide to peptides on the 2026 WADA list covers the sections.

In laboratories, degarelix has been studied in rats, monkeys and in vitro histamine-release tests (Broqua et al., 2002). The label adds that it “caused reversible infertility in male rats.” For research labels in general, see what research use only means.

Frequently asked questions about degarelix

Is degarelix a GnRH agonist or antagonist?

An antagonist. It blocks pituitary GnRH receptors. Agonists such as goserelin, leuprolide and triptorelin stimulate them first.

Does degarelix cause a testosterone surge?

In the pivotal trial, testosterone fell to castration levels by day 3 in about 96% of men on degarelix. None on leuprolide reached that level by day 3.

Is degarelix related to cetrorelix and ganirelix?

All three are GnRH antagonists. Their approved uses differ. See our cetrorelix and ganirelix guides.

Is degarelix safer for the heart than leuprolide?

Not proven. The PRONOUNCE trial found no significant difference at one year and stopped early. Its authors called the question unresolved.

Is degarelix banned in sport?

WADA’s 2026 list does not name it. Athletes should check with their anti-doping organization.

What to know now

  • What it is: a ten-amino-acid GnRH receptor antagonist, 1632.3 g/mol.
  • First approval: December 24, 2008, as Firmagon.
  • Approved use: advanced prostate cancer.
  • Key trial: noninferior to leuprolide for testosterone suppression over one year, with faster suppression.
  • Side effects: local site reactions, hot flashes and liver enzyme increases lead the label; no boxed warning.
  • Sport: not named on WADA’s 2026 list; check with your anti-doping organization.

What we’re watching

Any update to the Firmagon label, last revised in February 2020. New data on the heart safety of GnRH antagonists versus agonists after PRONOUNCE. And WADA’s 2027 Prohibited List, due to take effect on January 1, 2027.

More for reproductive system

All 12 compounds for reproductive system

Sources: Ferring Pharmaceuticals Inc 2020, FIRMAGON (degarelix) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: Original new drug approvals, Drugs@FDA: Original new drug approvals, December 2008; National Center for Biotechnology Information. PubChem compound summary for CID 16136245, PubChem compound summary for CID 16136245, Degarelix; Klotz 2008, BJU International, 102; Ferring Pharmaceuticals. ClinicalTrials.gov record for the CS21 phase 3 degarelix trial in prostate cancer (ClinicalTrials.gov ID NCT00295750). Retrieved November 17, ClinicalTrials.gov record for the CS21 phase 3 degarelix trial in prostate cancer; Lopes 2021, Circulation, 144; Ferring Pharmaceuticals. A trial comparing cardiovascular safety of degarelix versus leuprolide in patients with advanced prostate cancer and cardiovascular disease (PRONOUNCE; ClinicalTrials.gov ID NCT02663908). Retrieved November 17; Broqua 2002, Journal of Pharmacology and Experimental Therapeutics, 301; World Anti-Doping Agency 2025, World Anti-Doping Code International Standard: Prohibited List 2026. All 9 citations

Back to the research library

References

  1. Ferring Pharmaceuticals Inc. (2020). FIRMAGON (degarelix) prescribing information (revised February 2020). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab11dd8a-0fd9-4013-89ab-e114557c7e4b
  2. U.S. Food and Drug Administration. Drugs@FDA: Original new drug approvals, December 2008 (FIRMAGON, NDA 022201). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process&reportSelectMonth=12&reportSelectYear=2008&rptName=0
  3. National Center for Biotechnology Information. PubChem compound summary for CID 16136245, Degarelix. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/16136245
  4. Klotz, L., Boccon-Gibod, L., Shore, N. D., et al. (2008). The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU International, 102(11), 1531–1538. https://doi.org/10.1111/j.1464-410X.2008.08183.x
  5. Ferring Pharmaceuticals. ClinicalTrials.gov record for the CS21 phase 3 degarelix trial in prostate cancer (ClinicalTrials.gov ID NCT00295750). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT00295750
  6. Lopes, R. D., Higano, C. S., Slovin, S. F., et al. (2021). Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: The primary results of the PRONOUNCE randomized trial. Circulation, 144(16), 1295–1307. https://doi.org/10.1161/CIRCULATIONAHA.121.056810
  7. Ferring Pharmaceuticals. A trial comparing cardiovascular safety of degarelix versus leuprolide in patients with advanced prostate cancer and cardiovascular disease (PRONOUNCE; ClinicalTrials.gov ID NCT02663908). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT02663908
  8. Broqua, P., Riviere, P. J., Conn, P. M., et al. (2002). Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: Degarelix. Journal of Pharmacology and Experimental Therapeutics, 301(1), 95–102. https://doi.org/10.1124/jpet.301.1.95
  9. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026 (in effect January 1, 2026). https://www.wada-ama.org/en/prohibited-list